Опыт применения генно-инженерного биологического препарата при гиперэозинофильном синдроме у ребенка, перенесшего коронавирусную инфекцию (обзор литературы и описание клинического случая)

Обоснование. Гиперэозинофильный синдром (ГЭС) — гетерогенная группа заболеваний, для которой характерны эозинофильная инфильтрация тканей и широкий спектр клинических проявлений. Остается открытым вопрос о патогенетической терапии данного состояния, поскольку часть пациентов рефрактерны к традиционному лечению. Описание клинического случая. В статье рассмотрены основные проблемы дифференциальной диагностики и современные подходы к лечению ГЭС в педиатрической практике, а также представлен редкий клинический случай первичного ГЭС у ребенка 14 лет. После проведения тщательного диагностического поиска и подтверждения диагноза пациентке была назначена терапия системными глюкокортикоидами, давшая временный эффект. Однако в дальнейшем, учитывая развитие тяжелого обострения при попытке отмены гормональной терапии, было инициировано лечение меполизумабом — гуманизированным моноклональным антителом к рецептору интерлейкина 5. Заключение. Ведение пациентов с ГЭС нередко представляет значительные трудности, что связано с полиморфизмом клинических проявлений, необходимостью исключения широкого спектра заболеваний и возможной рефрактерностью к стандартной терапии. Применение генно-инженерного биологического препарата продемонстрировало высокую эффективность, позволив преодолеть зависимость от глюкокортикоидов и предотвратить развитие их побочных эффектов.

1. Gotlib I. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am I Hematol. 2014;89(3):325–337. doi: https://doi.org/10.1002/ajh.23664

2. Горячкина Л.А., Терехова Е.П. Идиопатический гиперэозинофильный синдром // Эффективная фармакотерапия. — 2012. — № 1. — С. 56–62.

3. Wang SA, Orazi A, Gotlib J, et al. The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023;98(8):1286–1306. doi: https://doi.org/10.1002/ajh.26966

4. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341(15):1112–1120. doi: https://doi.org/10.1056/ NEJM199910073411503

5. Kelemen K, Saft L, Craig FE, et al. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. Am J Clin Pathol. 2021;155(2):179–210. doi: https://doi.org/10.1093/ajcp/aqaa244

6. Tzankov A, Reichard KK, Hasserjian RP, et al. Updates on eosinophilic disorders. Virchows Arch. 2023;482(1):85–97. doi: https://doi.org/10.1007/s00428-022-03402-8

7. Caminati M, Brussino L, Carlucci M, et al. Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC). Cells. 2024;13(14):1180. doi: https://doi.org/10.3390/cells13141180

8. Меликян А.Л., Ковригина А.М., Суборцева И.Н., Шуваев В.А. Клинические рекомендации по диагностике и лечению миелопролиферативных заболеваний, протекающих с эозинофилией. — 113 с. Доступно по: https://npngo.ru/uploads/media_document/288/b44482ac-441a-4de2-8777-2a689a6bdaa5.pdf. Ссылка активна на 03.04.2026.

9. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–1719. doi: https://doi.org/10.1038/s41375-022-01613-1

10. Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(5):946–968. doi: https://doi.org/10.1002/ajh.27287

11. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54(1):1–27.

12. Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78(1):47–59. doi: https://doi.org/10.1111/all.15544

13. Белоглазов В.А., Ушаков А.В., Соколова Л.В. и др. Трудности диагностики идиопатического гиперэозинофильного синдрома // Таврический медико-биологический вестник. — 2017. — Т. 20. — № 2. — С. 140–143.

14. Akuthota P, Weller PF. Spectrum of Eosinophilic End-Organ Manifestations. Immunol Allergy Clin North Am. 2015;35(3):403– 411. doi: https://doi.org/10.1016/j.iac.2015.04.002

15. Requena G, van den Bosch J, Akuthota P, et al. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review. J Allergy Clin Immunol Pract. 2022;10(8):2125–2134. doi: https://doi.org/10.1016/j.jaip.2022.03.034

16. Dispenza MC, Bochner BS. Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes. Curr Hematol Malig Rep. 2018;13(3):191–201. doi: https://doi.org/10.1007/s11899-018-0448-8

17. Chen H, Raza HK, Jing J, et al. Hypereosinophilic syndrome with central nervous system involvement: Two case reports and literature review. Brain Inj. 2017;31(12):1695–1700. doi: https://doi.org/10.1080/02699052.2017.1357835

18. Mormile M, Mormile I, Fuschillo S, et al. Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice. Int J Mol Sci. 2023;24(8):7254. doi: https://doi.org/10.3390/ijms24087254

19. Kuang FL, Curtin BF, Alao H, et al. Single-Organ and Multisystem Hypereosinophilic Syndrome Patients with Gastrointestinal Manifestations Share Common Characteristics. J Allergy Clin Immunol Pract. 2020;8(8):2718–2726.e2. doi: https://doi.org/10.1016/j.jaip.2020.04.025

20. Locke M, Suen RM, Williamson AK, Nieto MJ. FIP1L1-PDGFRA Clonal Hypereosinophilic Syndrome With Eosinophilic Myocarditis and Intracardiac Thrombus. Cureus. 2023;15(8):e43138. doi: https://doi.org/10.7759/cureus.43138

21. Groh M, Rohmer J, Etienne N, et al. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. Orphanet J Rare Dis. 2023;18(1):100. doi: https://doi.org/10.1186/s13023-023-02696-4

22. Thomsen GN, Christoffersen MN, Lindegaard HM, et al. The multidisciplinary approach to eosinophilia.Front Oncol. 2023;13:1193730. doi: https://doi.org/10.3389/fonc.2023.1193730

23. Балыкова Л.А., Краснопольская А.В., Ширманкина М.В. и др. Гиперэозинофильный синдром: современные подходы к молекулярно-генетической диагностике и терапии генно-инженерными биологическими препаратами // Медицина и биотехнологии. — 2025. — Т. 1. — № 1. — С. 13–23. — doi: https://doi.org/10.15507/3034-6231.001.202501.013-023

24. Яковлев Я.Я., Рудковская Л.В., Лавринова О.В. и др. Тяжелый гиперэозинофильный синдром с поражением кожи у детей в практике педиатра // Мать и дитя в Кузбассе. — 2022. — № 3. — С. 69–77. — doi: https://doi.org/10.24412/2686-7338-2022-3-69-77

25. Khoury P, Abiodun AO, Holland-Thomas N, et al. Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids. J Allergy Clin Immunol Pract. 2018;6(1):190–195. doi: https://doi.org/10.1016/j.jaip.2017.06.006

26. Hwee J, Huynh L, Du S., et al. Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization. Ann Allergy Asthma Immunol. 2023;130(6):768–775. doi: https://doi.org/10.1016/j.anai.2023.02.022

27. Schwaab J, Naumann N, Luebke J, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020;95(7):824–833. doi: https://doi.org/10.1002/ajh.25825

28. Freyer CW, Hughes ME, Carulli A, et al. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement. Expert Rev Anticancer Ther. 2023;23(4):351–359. doi: https://doi.org/10.1080/14737140.2023.2192930

29. King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. J Invest Dermatol. 2017;137(4):951–954. doi: https://doi.org/10.1016/j.jid.2016.10.044

30. Alves Júnior JM, Prota FE, Villagelin D, et al. Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Metaanalysis. Clinics (Sao Paulo). 2021;76:e3271. doi: https://doi.org/10.6061/clinics/2021/e3271

31. Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397– 1405. doi: https://doi.org/10.1016/j.jaci.2020.08.037

32. Chen MM, Roufosse F, Wang SA, et al. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. J Allergy Clin Immunol Pract. 2022;10(5):1217–1228.e3. doi: https://doi.org/10.1016/j.jaip.2022.02.006

33. Kuang FL, Fay MP, Ware J, et al. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. J Allergy Clin Immunol Pract. 2018;6(5):1518–1527.e5. doi: https://doi.org/10.1016/j.jaip.2018.04.033

34. Rothenberg ME, Roufosse F, Faguer S. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.J Allergy Clin Immunol Pract. 2022;10(9):2367– 2374.e3. doi: https://doi.org/10.1016/j.jaip.2022.04.037

35. Coussement G, Catherine J, Roufosse F. Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program. J Leukoc Biol. 2024;116(5):1021–1032. doi: https://doi.org/10.1093/jleuko/qiae152

36. Schwarz C, Müller T, Lau S, et al. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood. Pediatr Allergy Immunol. 2018;29(1):28–33. doi: https://doi.org/10.1111/pai.12809

37. Jue JH, Shim YJ, Park S, et al. Korean Adolescent Patient with Manifestations of Lymphocyte Variant Hypereosinophilic Syndrome and Episodic Angioedema with Eosinophilia, Treated with Reslizumab. Iran J Allergy Asthma Immunol. 2022;21(2):215–218. doi: https://doi.org/10.18502/ijaai.v21i2.9229

38. Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome. N Engl J Med. 2019;380(14):1336–1346. doi: https://doi.org/10.1056/NEJMoa1812185

39. A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON). In: ClinicalTrials.gov: Website. Available online: https://clinicaltrials.gov/study/NCT04191304. Accessed on April 03, 2026.

40. Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY). In: ClinicalTrials.gov: Website. Available online: https://clinicaltrials.gov/study/NCT05334368. Accessed on April 03, 2026.

41. Fujii K, Takahashi H, Hayakawa N, Iwasaki Y. Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab. Respirol Case Rep. 2020;8(8):e00665. doi: https://doi.org/10.1002/rcr2.665

42. Kosałka-Węgiel J, Milewski M, Siwiec A, et al. Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α — benralizumab. Cent Eur J Immunol. 2021;46(3):395–397. doi: https://doi.org/10.5114/ceji.2021.108259

43. Holle JU, Moosig F. Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis. Z Rheumatol. 2023;82(4):307–320. doi: https://doi.org/10.1007/s00393-023-01345-2

44. Suzuki S, Suzuki K, Ichikawa T, et al. Acute exacerbation of idiopathic hypereosinophilic syndrome following asymptomatic coronavirus disease 2019: a case report. J Med Case Rep. 2022;16(1):324. doi: https://doi.org/10.1186/s13256-022-03543-z

45. Karampoor S, Afrashteh F, Rahmani S, Laali A. Eosinophilic granulomatosis with polyangiitis after COVID-19: A case report. Respir Med Case Rep. 2022;38:101702. doi: https://doi.org/10.1016/j.rmcr.2022.101702

46. Shah S, Danda D, Kavadichanda C, et al. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatol Int. 2020;40(10):1539– 1554. doi: https://doi.org/10.1007/s00296-020-04639-9

47. Kim DM, Seo JW, Kim Y, et al. Eosinophil-mediated lung inflammation associated with elevated natural killer T cell response in COVID-19 patients. Korean J Intern Med. 2022;37(1):201–209. doi: https://doi.org/10.3904/kjim.2021.093

48. Sherafati A, Rahmanian M, Sattarzadeh Badkoubeh R. et al. Hyepereosiniphilic syndrome and COVID-19: 2 case reports. J Cardiothorac Surg. 2023;18(1):158. doi: https://doi.org/10.1186/s13019-023-02241-1

49. Mapelli M, Cefalù C, Zaffalon D, et al. Hypereosinophilic syndrome onset with Loeffler’s endocarditis after COVID-19 infection. Eur Heart J Cardiovasc Imaging. 2022;23(10):e472. doi: https://doi.org/10.1093/ehjci/jeac150

50. Espinoza DF, Wetzler L, Holland N, et al. COVID-19 infection in hypereosinophilic syndrome: A survey-based analysis. J Allergy Clin Immunol Pract. 2022;10(5):1371–1373.e20. doi: https://doi.org/10.1016/j.jaip.2022.02.019

51. Otani IM, Anilkumar AA, Newbury RO, et al. Anti-IL-5 Therapy Reduces Mast Cells and IL-9 Cells in Paediatric Eosinophilic Esophagitis. J Allergy Clin Immunol. 2013;131(6):1576–1582. doi: https://doi.org/10.1016/j.jaci.2013.02.042

52. Armoni Domany K, Shiran SI, Adir D, et al. The Effect of Mepolizumab on the Lungs in a Boy with Hypereosinophilic Syndrome. Am J Respir Crit Care Med. 2020;202(2):34–35. doi: https://doi.org/10.1164/rccm.201907-1376IM

53. Fox E, Cohen B, Treyster Z. Successful use of mepolizumab for severe hypereosinophilic vasculitis with c-ANCA positivity in a previously healthy 7-year-old boy. J Allergy Clin Immunol Glob. 2022;2(1):124– 126. doi: https://doi.org/10.1016/j.jacig.2022.09.009

54. Forero Molina MA, Coffey KE, Chong HJ. Successful treatment of idiopathic hypereosinophilic syndrome with benralizumab in a pediatric patient. J Allergy Clin Immunol Pract. 2021;9(1):589–590. doi: https://doi.org/10.1016/j.jaip.2020.08.034